This 2023 review highlights the therapeutic potential of mebendazole (MBZ), a benzimidazole antiparasitic agent, as a repurposed drug for brain cancers, particularly glioblastoma and medulloblastoma. MBZ exerts anti-cancer effects by disrupting microtubule polymerization, inhibiting angiogenesis, inducing apoptosis, and modulating key oncogenic pathways such as Hedgehog signaling. Preclinical models demonstrate MBZ's
